With broadened use of newer prostate-specific membrane antigen (PSMA)–based radioligands to identify the location of prostate cancer using PET, the treatment of BCR is rapidly changing to more personalized and targeted approaches (4). The gene discussed is FOLH1; the disease is prostate cancer.